PT71755B - Process for preparing 4-(substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase - Google Patents
Process for preparing 4-(substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidaseInfo
- Publication number
- PT71755B PT71755B PT71755A PT7175580A PT71755B PT 71755 B PT71755 B PT 71755B PT 71755 A PT71755 A PT 71755A PT 7175580 A PT7175580 A PT 7175580A PT 71755 B PT71755 B PT 71755B
- Authority
- PT
- Portugal
- Prior art keywords
- pyrroline
- hydroxy
- glycolic acid
- acid oxidase
- preparing
- Prior art date
Links
- -1 4-(substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-dione Chemical class 0.000 title abstract 2
- 108010062584 glycollate oxidase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 206010038478 Renal lithiasis Diseases 0.000 abstract 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/074,465 US4298743A (en) | 1979-09-11 | 1979-09-11 | 4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PT71755A PT71755A (en) | 1980-09-01 |
| PT71755B true PT71755B (en) | 1982-03-19 |
Family
ID=22119703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT71755A PT71755B (en) | 1979-09-11 | 1980-08-29 | Process for preparing 4-(substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4298743A (OSRAM) |
| EP (1) | EP0025232B1 (OSRAM) |
| JP (1) | JPS5646809A (OSRAM) |
| AT (1) | ATE2271T1 (OSRAM) |
| DE (1) | DE3061688D1 (OSRAM) |
| DK (1) | DK384280A (OSRAM) |
| ES (1) | ES494933A0 (OSRAM) |
| GR (1) | GR70200B (OSRAM) |
| PT (1) | PT71755B (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4379791A (en) * | 1979-09-11 | 1983-04-12 | Merck & Co., Inc. | 4-(Substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase |
| US4700901A (en) * | 1985-08-19 | 1987-10-20 | Breville R & D Pty. Limited | Food processors |
| JP2829451B2 (ja) * | 1990-11-30 | 1998-11-25 | 大塚製薬株式会社 | 活性酸素抑制剤 |
| MY128323A (en) * | 1996-09-30 | 2007-01-31 | Otsuka Pharma Co Ltd | Thiazole derivatives for inhibition of cytokine production and of cell adhesion |
| US6313156B1 (en) | 1999-12-23 | 2001-11-06 | Icos Corporation | Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors |
| DE10029077A1 (de) * | 2000-06-13 | 2001-12-20 | Bayer Ag | Thiazolylsubstituierte Heterocyclen |
| ES2572030T3 (es) * | 2001-08-10 | 2017-07-19 | Shionogi & Co., Ltd. | Agente antiviral |
| US6858614B2 (en) * | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenolic guanidine sodium channel blockers |
| US6858615B2 (en) * | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US6903105B2 (en) | 2003-02-19 | 2005-06-07 | Parion Sciences, Inc. | Sodium channel blockers |
| US7745442B2 (en) | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
| US20070078121A1 (en) | 2004-12-23 | 2007-04-05 | Flynn Daniel L | Enzyme modulators and treatments |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| AU2008242767A1 (en) | 2007-04-20 | 2008-10-30 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| CA2742007C (en) | 2008-10-29 | 2014-07-08 | Deciphera Pharmaceuticals, Llc | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| CN108658876A (zh) | 2012-12-17 | 2018-10-16 | 帕里昂科学公司 | 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物 |
| JP6392242B2 (ja) | 2012-12-17 | 2018-09-19 | パリオン・サイエンシィズ・インコーポレーテッド | 粘膜への水分付与が不十分であることが好都合である疾患の治療に有用なクロロ−ピラジンカルボキサミド誘導体 |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
| EP3746059A1 (en) | 2018-01-31 | 2020-12-09 | Deciphera Pharmaceuticals, LLC | Combination therapy for the treatment of gastrointestinal stromal tumors |
| WO2019152719A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of mastocytosis |
| US12509456B2 (en) | 2019-03-11 | 2025-12-30 | Deciphera Pharmaceuticals, Llc | Solid state forms of ripretinib |
| CA3150433A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| DK4084779T3 (da) | 2019-12-30 | 2024-12-16 | Deciphera Pharmaceuticals Llc | Sammensætninger af 1-(4-brom-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro- 1,6-naphthyridin-3-yl)-2-fluorphenyl)-3-phenylurea |
| CN119970649A (zh) | 2019-12-30 | 2025-05-13 | 德西费拉制药有限责任公司 | 非晶型激酶抑制剂制剂及其使用方法 |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE599556A (OSRAM) * | 1960-02-01 | |||
| US3340263A (en) * | 1964-02-14 | 1967-09-05 | Ciba Geigy Corp | Amino-pyrroles |
| GB1127875A (en) * | 1967-03-23 | 1968-09-18 | Parke Davis & Co | 4-(5-nitro-2-furyl) thiazolyl hydantoins and hydrouracils |
| GB1304174A (OSRAM) * | 1969-03-07 | 1973-01-24 |
-
1979
- 1979-09-11 US US06/074,465 patent/US4298743A/en not_active Expired - Lifetime
-
1980
- 1980-08-29 PT PT71755A patent/PT71755B/pt unknown
- 1980-09-08 GR GR62835A patent/GR70200B/el unknown
- 1980-09-10 ES ES494933A patent/ES494933A0/es active Granted
- 1980-09-10 AT AT80105409T patent/ATE2271T1/de not_active IP Right Cessation
- 1980-09-10 DE DE8080105409T patent/DE3061688D1/de not_active Expired
- 1980-09-10 DK DK384280A patent/DK384280A/da not_active Application Discontinuation
- 1980-09-10 EP EP80105409A patent/EP0025232B1/en not_active Expired
- 1980-09-11 JP JP12536980A patent/JPS5646809A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GR70200B (OSRAM) | 1982-08-31 |
| ES8105996A1 (es) | 1981-07-01 |
| DK384280A (da) | 1981-03-12 |
| EP0025232B1 (en) | 1983-01-19 |
| EP0025232A1 (en) | 1981-03-18 |
| DE3061688D1 (en) | 1983-02-24 |
| US4298743A (en) | 1981-11-03 |
| ES494933A0 (es) | 1981-07-01 |
| PT71755A (en) | 1980-09-01 |
| ATE2271T1 (de) | 1983-02-15 |
| JPS5646809A (en) | 1981-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT71755B (en) | Process for preparing 4-(substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase | |
| PT71368B (en) | Process for preparing 4-substituted-3-hydroxy-3-pirroline-2,5-dione inhibitors of glycolic acid oxidase | |
| ZA806788B (en) | 4-(5(and 4)-subsittuted-2-thienyl)-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic and oxidase | |
| IE811431L (en) | Pyrazinyl oxadiazoles | |
| NO881697D0 (no) | Verktoeyenhet, verktoeydeler og fremgangsmaate for sammensetting av delene. | |
| GB2014981A (en) | Substituted propanolamine and morpholine derivatives | |
| IL67235A (en) | 3-(1-substituted-4-piperidyl)-1,2-benzisoxazoles,a process for the preparation thereof,and pharmaceutical compositions comprising the same | |
| NO852326L (no) | Fremgangsmaate ved behandling av ildfaste gjenstander. | |
| DE3882775D1 (de) | Zusammensetzung zur behandlung von parodontaler krankheit. | |
| DE3788057D1 (de) | Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen. | |
| DE3886913D1 (de) | Verfahren zur Herstellung von flüssigen alkylierten 2-(2-Hydroxyphenyl)-benztriazol-Gemischen. | |
| DE3869590D1 (de) | Mischung zur behandlung von hypercholesterolemie. | |
| ZA886097B (en) | Pharmaceutical composition for the treatment of psoriasis | |
| PT72772A (en) | Process for preparing 4-alkylsubstituted-3-hidroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase | |
| ZA806786B (en) | 4-substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase | |
| NO885287D0 (no) | Fremgangsmÿte ved behandling av boreslam. | |
| HUT36783A (en) | Process for preparing 1,7-diphenyl-3-methyl-aza-7-cyano-8-methyl-nonane | |
| NO884635D0 (no) | Fremgangsmaate for behandling av most. | |
| ES8609326A1 (es) | Un procedimiento para la preparacion de nuevas 1-(aril sustituido)dihidro 1h pirrolizin-3,5-(h,6h)-dionas | |
| NO892171D0 (no) | Fremgangsmaate for stabilisering, konsolidering og lagringav avfallsmaterialer. | |
| NO880773L (no) | Framgangsmaate for behandling av pulp for kartong. | |
| PL212775A1 (pl) | Zestaw do chirurgicznego leczenia zlaman kosci,zwlaszcza zuchwy | |
| ATE95062T1 (de) | Zusammensetzung zur behandlung von krebs, gekennzeichnet durch ueberexpression des c-fmsproto-onkogens. | |
| ATE64683T1 (de) | Zusammensetzung zur behandlung von haemorroiden. |